Stock Market Stories and Insights

The fundamental rationale behind this short perspective is to break down our forecasting of Ocean for private investors. We will try to forecast Ocean Power outlook for October.
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
Oracle Average Equity is relatively stable at the moment as compared to the past year. The company's current value of Average Equity is estimated at 13.93 Billion. Enterprise Value is expected to hike to about 227.4 B this year, although the value of Invested Capital will most likely fall to nearly 87.7 B. If you have been following Oracle you may be considering acquiring. Let's check if steady fundamental indicators will continue to push the price to hike for Oracle's stakeholders. Will stakeholders continue to hold, or should we expect a sell-off?
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
Today we may see the proof that Autoscope Technologies would recover much slower from the current slip as its shares went up 0.79% to Mitcham Industries's 4.2254%. As many rational traders are trying to avoid technology space, it makes sense to digest Mitcham Industries a little further and understand how it stands against Autoscope Technologies and other similar entities. We are going to discuss some of the competitive aspects of both Mitcham and Autoscope.
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
Sea Change Intl is scheduled to announce its earnings tomorrow. Sea Change Average Assets are projected to decrease significantly based on the last few years of reporting. The past year's Average Assets were at 178.64 Million. The current year Average Equity is expected to grow to about 141.7 M, whereas Net Income Per Employee is forecasted to decline to (74.9 K). While some millenniums are indifferent towards technology space, it makes sense to go over Sea Change Intl as a unique investment alternative. What exactly are Sea Change shareholders getting in October?
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
It appears Virco MFG may not recover as fast as we have hopped for as its price went down 1.9% today. The entity current daily volatility is 4.3 percent, with a beta of 0.42 and an alpha of 0.46 over DOW. As many of us are getting excited about current market fluctuations it is important to go over Virco MFG based on its technical indicators. We will evaluate why we are still optimistic in anticipation of a recovery.
  over two weeks ago at Macroaxis 
By Ellen Johnson
Ellen Johnson
Matrix Service Receivables Turnover is fairly stable at the moment as compared to the past year. Matrix Service reported Receivables Turnover of 3.88 in 2021. Inventory Turnover is likely to rise to 109.57 in 2022, whereas Net Income Per Employee is likely to drop (13.6 K) in 2022. While many traders are getting carried away by overanalyzing industrials space, it is reasonable to break down Matrix Service. We will analyze why Matrix Service investors may still consider a stake in the business. In this post, I will also go over a few different drivers affecting Matrix Service's products and services, and explain how it may impact Matrix Service investors.
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
It looks like Eaton Vance will be up for a correction way faster as its share price whent up 0.88% today to Four Seasons's 0.0714%. As many rational traders are trying to avoid consumer defensive space, it makes sense to review Four Seasons Education a little further and understand how it stands against Eaton Vance and other similar entities. We are going to break down some of the competitive aspects of both Four Seasons and Eaton.
  over two weeks ago at Macroaxis 
By Ellen Johnson
Ellen Johnson
The current year Price to Sales Ratio is expected to grow to 3.16, whereas EBITDA Margin is forecasted to decline to (12.53) . As many investors are getting excited about pharmaceutical products space, it is fair to digest Cerevel Therapeutics Hldg. We will evaluate why recent Cerevel Therapeutics price moves suggest a bounce in October. Here I will also expose some primary fundamental factors affecting Cerevel Therapeutics' services, and outline how it will impact the outlook for investors this year.
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik
Today's short post will review Lifestance Health as your potential position. We will break down the question of why private investors should continue to be confident in Lifestance Health outlook.
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
The stock is currently experiencing an active downward rally. Glaukos Corp Working Capital is relatively stable at the moment as compared to the past year. Glaukos Corp reported last year Working Capital of 422.77 Million. As of 09/10/2022, Long Term Debt to Equity is likely to grow to 0.67, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (1.6 M). While some baby boomers are getting worried about healthcare space, it is reasonable to sum up Glaukos Corp as an investment alternative. We will check if the company can maintain a respectable level of debt while minimizing operating losses.
  over two weeks ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik